Compare Stocks: ZTS, SNY, GSK, and TAK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GSK GSK	$46.50 -0.1%	$50.02	$42.85 ▼ $61.69	$94.14B	0.33	4.23 million shs	8.54 million shs
SNY Sanofi	$40.07 -0.4%	$42.99	$39.18 ▼ $52.68	$97.53B	0.33	3.11 million shs	2.10 million shs
TAK Takeda Pharmaceutical	$18.74 +1.2%	$18.15	$12.99 ▼ $19.10	$59.34B	-0.07	2.56 million shs	2.04 million shs
ZTS Zoetis	$74.77 +2.3%	$73.92	$68.77 ▼ $148.30	$30.20B	0.74	4.53 million shs	2.91 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GSK GSK	-0.05%	-1.19%	-4.45%	-11.89%	+7.23%
SNY Sanofi	-0.40%	+0.38%	-6.49%	-7.89%	-17.89%
TAK Takeda Pharmaceutical	+1.24%	+4.85%	+2.74%	+13.17%	+30.83%
ZTS Zoetis	+2.32%	+7.40%	+1.88%	-0.95%	-47.93%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GSK GSK	$46.50 -0.1%	$50.02	$42.85 ▼ $61.69	$94.14B	0.33	4.23 million shs	8.54 million shs
SNY Sanofi	$40.07 -0.4%	$42.99	$39.18 ▼ $52.68	$97.53B	0.33	3.11 million shs	2.10 million shs
TAK Takeda Pharmaceutical	$18.74 +1.2%	$18.15	$12.99 ▼ $19.10	$59.34B	-0.07	2.56 million shs	2.04 million shs
ZTS Zoetis	$74.77 +2.3%	$73.92	$68.77 ▼ $148.30	$30.20B	0.74	4.53 million shs	2.91 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GSK GSK	-0.05%	-1.19%	-4.45%	-11.89%	+7.23%
SNY Sanofi	-0.40%	+0.38%	-6.49%	-7.89%	-17.89%
TAK Takeda Pharmaceutical	+1.24%	+4.85%	+2.74%	+13.17%	+30.83%
ZTS Zoetis	+2.32%	+7.40%	+1.88%	-0.95%	-47.93%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GSK GSK	2.05	Hold	$55.33	19.01% Upside
SNY Sanofi	2.38	Hold	$49.50	23.53% Upside
TAK Takeda Pharmaceutical	2.50	Moderate Buy	N/A	N/A
ZTS Zoetis	2.32	Hold	$101.08	35.18% Upside

Current Analyst Ratings Breakdown

Latest ZTS, SNY, GSK, and TAK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	GSK GSK	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$70.00
10/9/2026	SNY Sanofi	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Peer Perform
10/8/2026	SNY Sanofi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)
10/8/2026	TAK Takeda Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
10/6/2026	GSK GSK	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
10/5/2026	SNY Sanofi	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
10/1/2026	GSK GSK	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell
10/1/2026	SNY Sanofi	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
10/1/2026	SNY Sanofi	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
10/1/2026	TAK Takeda Pharmaceutical	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
9/29/2026	GSK GSK	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GSK GSK	$43.07B	2.18	$6.00 per share	7.75	$10.32 per share	4.51
SNY Sanofi	$49.35B	1.97	$7.04 per share	5.69	$33.27 per share	1.20
TAK Takeda Pharmaceutical	$28.32B	2.12	$3.14 per share	5.97	$15.41 per share	1.22
ZTS Zoetis	$9.47B	3.26	$7.74 per share	9.66	$7.56 per share	9.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GSK GSK	$7.54B	$3.20	14.54	9.30	2.09	14.56%	43.23%	11.60%	10/28/2026 (Estimated)
SNY Sanofi	$8.84B	$1.91	20.98	7.65	1.22	8.66%	14.19%	7.95%	10/30/2026 (Estimated)
TAK Takeda Pharmaceutical	-$1.01B	$0.34	55.10	13.38	N/A	3.80%	10.95%	5.34%	10/29/2026 (Estimated)
ZTS Zoetis	$2.67B	$6.07	12.32	11.81	1.70	27.49%	74.89%	18.59%	11/5/2026 (Estimated)

Latest ZTS, SNY, GSK, and TAK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	ZTS Zoetis	$1.52	N/A	N/A	N/A	$2.30 billion	N/A
10/30/2026	Q3 2026	SNY Sanofi	$1.72	N/A	N/A	N/A	$15.24 billion	N/A
10/29/2026	Q2 2027	TAK Takeda Pharmaceutical	$0.1477	N/A	N/A	N/A	$7.32 billion	N/A
10/28/2026	Q3 2026	GSK GSK	$1.34	N/A	N/A	N/A	$11.79 billion	N/A
8/6/2026	Q2 2026	ZTS Zoetis	$1.85	$1.87	+$0.02	$1.65	$2.50 billion	$2.47 billion
7/30/2026	Q2 2026	SNY Sanofi	N/A	$2.41	N/A	$0.17	N/A	$13.36 billion
7/30/2026	Q1 2027	TAK Takeda Pharmaceutical	$0.41	$0.95	+$0.54	$0.22	$7.13 billion	$7.50 billion
7/28/2026	Q2 2026 & Strategy update	GSK GSK	$1.27	$1.36	+$0.09	$0.28	$11.02 billion	$11.14 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GSK GSK	$1.77	3.81%	-7.86%	55.31%	N/A
SNY Sanofi	$1.76	4.39%	+6.46%	92.15%	N/A
TAK Takeda Pharmaceutical	$0.48	2.56%	-6.89%	141.18%	N/A
ZTS Zoetis	$2.12	2.84%	+20.11%	34.93%	14 Years

Latest ZTS, SNY, GSK, and TAK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
10/8/2026	ZTS Zoetis	quarterly	$0.53	2.9%	10/30/2026	10/30/2026	12/1/2026
7/28/2026	GSK GSK	quarterly	$0.4515	3.65%	8/14/2026	8/14/2026	10/8/2026
1/1/2100	GSK GSK	quarterly	$0.4206	4.3%	8/15/2025	8/15/2025	10/9/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GSK GSK	0.81	0.82	0.52
SNY Sanofi	0.21	0.99	0.64
TAK Takeda Pharmaceutical	0.58	1.14	0.62
ZTS Zoetis	2.87	3.08	1.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GSK GSK	15.74%
SNY Sanofi	14.03%
TAK Takeda Pharmaceutical	9.17%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
GSK GSK	10.00%
SNY Sanofi	1.00%
TAK Takeda Pharmaceutical	0.04%
ZTS Zoetis	0.22%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GSK GSK	66,841	2.02 billion	1.82 billion	Optionable
SNY Sanofi	74,846	2.42 billion	2.40 billion	Optionable
TAK Takeda Pharmaceutical	47,000	3.20 billion	3.20 billion	Optionable
ZTS Zoetis	14,500	413.22 million	412.32 million	Optionable

ZTS, SNY, GSK, and TAK Headlines

Recent News About These Companies

Zoetis (ZTS) Outpaces Stock Market Gains: What You Should Know

October 9 at 7:15 PM | zacks.com

Zoetis Inc. (NYSE:ZTS) Plans Quarterly Dividend of $0.53

October 9 at 7:29 AM | marketbeat.com

Zoetis (ZTS) Declares $0.53 Quarterly Dividend; 2.9% Yield

October 8 at 11:55 PM | streetinsider.com

Zoetis (ZTS) Says Study Shows Simparica Trio Outperformed A Rival On Resistant Heartworm

October 8 at 6:55 PM | finance.yahoo.com

Zoetis Declares Fourth-Quarter Dividend, Signals Ongoing Strength

October 8 at 5:10 PM | tipranks.com

Zoetis Declares Fourth Quarter 2026 Dividend

October 8 at 5:00 PM | businesswire.com

Zoetis hits a new 52-week low as Zoetis stock gains 2.86 percent

October 6, 2026 | ad-hoc-news.deA

New Peer-Reviewed Publication on Laboratory Study That Demonstrated Simparica Trio® Protected 3x More Dogs From Infection With a Resistant Heartworm Isolate Than NexGard® Plus1

October 6, 2026 | businesswire.com

MarketBeat cites Hold consensus for Zoetis stock

October 5, 2026 | ad-hoc-news.deA

40,294 Zoetis Inc. $ZTS Shares Purchased by Rockland Trust Co.

October 5, 2026 | marketbeat.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zoetis (ZTS), Eli Lilly & Co (LLY) and Liquidia Technologies (LQDA)

October 2, 2026 | theglobeandmail.com

Zoetis (ZTS) Has a Huge Animal Health Moat. Is It Starting to Crack?

October 1, 2026 | insidermonkey.com

Zoetis (ZTS) Stock Sinks As Market Gains: Here's Why

October 1, 2026 | zacks.com

Zoetis (ZTS) Stock Sinks As Market Gains: Here's Why

October 1, 2026 | finance.yahoo.com

Zoetis Inc. (NYSE:ZTS) Stock Has Consensus Target Price of $101.08

October 1, 2026 | americanbankingnews.com

Zoetis Inc. (NYSE:ZTS) Stock Rated "Hold" by Wall Street Analysts

October 1, 2026 | marketbeat.com

Zoetis (NYSE:ZTS) Hits New 1-Year Low - What's Next?

September 30, 2026 | marketbeat.com

Zoetis: Priced For The Worst, Worth Buying

September 30, 2026 | seekingalpha.com

483,862 Zoetis Inc. $ZTS Shares Sold by Envestnet Asset Management Inc.

September 29, 2026 | marketbeat.com

Zoetis Inc. $ZTS Stock Sold by QRG Capital Management Inc.

September 26, 2026 | marketbeat.com

Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note

September 24, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ZTS, SNY, GSK, and TAK Company Descriptions

GSK NYSE:GSK

$46.50 -0.05 (-0.10%)

Closing price 10/9/2026 03:59 PM Eastern

Extended Trading

$46.56 +0.07 (+0.15%)

As of 10/9/2026 07:55 PM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Sanofi NASDAQ:SNY

$40.07 -0.16 (-0.40%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$40.17 +0.10 (+0.26%)

As of 10/9/2026 07:52 PM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Takeda Pharmaceutical NYSE:TAK

$18.74 +0.22 (+1.16%)

Closing price 10/9/2026 03:59 PM Eastern

Extended Trading

$18.20 -0.54 (-2.86%)

As of 10/9/2026 07:30 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Zoetis NYSE:ZTS

$74.77 +1.69 (+2.32%)

Closing price 10/9/2026 03:59 PM Eastern

Extended Trading

$74.41 -0.36 (-0.48%)

As of 10/9/2026 07:55 PM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ZTS, SNY, GSK, and TAK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ZTS, SNY, GSK, and TAK Earnings

Compare Dividends

Latest ZTS, SNY, GSK, and TAK Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ZTS, SNY, GSK, and TAK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ZTS, SNY, GSK, and TAK Company Descriptions

GSK NYSE:GSK

Sanofi NASDAQ:SNY

Takeda Pharmaceutical NYSE:TAK

Zoetis NYSE:ZTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools